Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma

Cancer Medicine
Tao CaiJie Xiao

Abstract

Glioblastoma (GBM) is the most common and lethal tumor of the central nervous system with highly infiltrative and resistant to chemotherapy. Temozolomide (TMZ) is widely used as the first-line treatment for the therapy of GBM. However, a considerable percentage inherent or acquired resistance in GBM accounts for many treatment failures of the TMZ chemotherapy. Therefore, a deeper understanding of the molecular characteristics underlying TMZ resistance and the identification of novel therapeutic target is urgent. Here, we show that MALAT1 was significantly upregulated in TMZ-resistant GBM cells. On the other hand, MALAT1 knockdown reduces TMZ resistance of GBM cells both in vitro and in vivo by inhibiting cell proliferation and promoting apoptosis. We also show that miR-101 overexpression reduced TMZ resistance of GBM cells and played an antagonistic role compared with MALAT1. Importantly, we demonstrate that MALAT1 promoted the chemoresistance through suppressing miR-101 signaling pathway via directly binding it in GBM cells. In conclusion, our study indicates that knockdown of MALAT1 reverses chemoresistance to TMZ via promoting miR-101 regulatory network in GBM and thus offers a novel prognostic marker and potential target fo...Continue Reading

References

Jul 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen YipDavid N Louis
Jul 15, 2009·Cancer Chemotherapy and Pharmacology·Meryem BektasHenry S Friedman
Feb 8, 2011·European Urology·James W F CattoTapio Visakorpi
Jan 23, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yu FanYong Liu
Jan 24, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Kang-xiao MaJian-wen Wu
Jun 6, 2015·Biochemical and Biophysical Research Communications·Tian TianZhaoming Li
Aug 19, 2015·Molecular and Cellular Endocrinology·Paweena ChunharojrithAnne Klibanski
Sep 27, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Chun-Lin ZhangZhong-Sheng Zhu
Mar 11, 2016·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·P D Delgado-López, E M Corrales-García
Aug 31, 2016·Advances in Experimental Medicine and Biology·Daniele FanaleAntonio Russo

❮ Previous
Next ❯

Citations

Jan 12, 2019·Human Gene Therapy. Clinical Development·Liang HanXudong Wu
Jul 31, 2019·BioMed Research International·Wenyuan ZhaoChaojun Duan
Apr 24, 2020·Molecular Medicine Reports·Jing ZhouHongmei Fu
Mar 17, 2020·Cancer Biomarkers : Section a of Disease Markers·Rui Liang, Youjia Tang
Sep 14, 2018·Frontiers in Oncology·Fabio CorràStefano Volinia
Aug 24, 2018·Briefings in Functional Genomics·Ryan ParkWen-Ming Chu
Jun 7, 2020·Non-coding RNA·Gayatri ArunDavid L Spector
Nov 1, 2020·Cells·Christian T StackhouseChristopher D Willey
Mar 9, 2020·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Wenxiao JiangXueqiong Zhu
Feb 27, 2021·Frontiers in Oncology·Omidvar RezaeiSoudeh Ghafouri-Fard
Apr 4, 2021·Genes·Parvaneh MahinfarBehzad Mansoori
Apr 4, 2021·Cancers·Maria Teresa Di MartinoPierfrancesco Tassone
Jan 25, 2020·Biochimica Et Biophysica Acta. Molecular Cell Research·Jintao LinWeifeng Mao
May 14, 2021·Journal of Hematology & Oncology·Sung-Hyun KimJae-Yeol Joo
Jul 3, 2021·Cancers·Javier Martinez-UserosJesus Garcia-Foncillas
Jun 29, 2021·Frontiers in Oncology·Soudeh Ghafouri-FardGuive Sharifi
Aug 8, 2021·International Journal of Molecular Sciences·Qiong WuArnold B Etame
Jan 14, 2022·Genes & Genomics·Agnik Haldar, Ajay Kumar Singh

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
flow cytometry
Assay
transgenic
PCR

Software Mentioned

GraphPad
GraphPad Prism
ImageJ

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis